Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.37 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.37 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.37 |
| ▸ | ACACB | O00763 | 2/20 | 0.37 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.36 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.36 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.36 |
| ▸ | TGM2 | P21980 | 1/20 | 0.35 |
| ▸ | ACACA | Q13085 | 1/20 | 0.35 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL240061 | 0.90 | HRH3 (0.39) | HRH3AOC3TPSAB1TPSD1TPSG1 | |
| SCHEMBL1727464 | 0.84 | HRH3 (0.42) | HRH3CHRM4ACACBTGM2TRPV3 | |
| SCHEMBL3265574 | 0.84 | TPSAB1 (0.40) | HSD11B1TPSAB1TPSD1TPSG1CHRM4 | |
| SCHEMBL5777613 | 0.81 | HRH3 (0.44) | HRH3AOC3HSD11B1ACACBTRPV3 | |
| SCHEMBL3265609 | 0.81 | CKS1B (0.41) | HSD11B1TPSAB1TPSD1TPSG1CHRM4 | |
| SCHEMBL240267 | 0.79 | PDE10A (0.44) | HRH3ACACBACACA | |
| SCHEMBL3265618 | 0.79 | CNR1 (0.41) | CHRM4 | |
| SCHEMBL3270231 | 0.78 | PTGES (0.44) | TPSAB1TPSD1TPSG1CHRM4SUV39H2 | |
| SCHEMBL3265488 | 0.78 | FAAH (0.40) | HRH3AOC3TPSAB1TPSD1TPSG1 | |
| SCHEMBL3270022 | 0.77 | SCD (0.43) | TPSAB1TPSD1TPSG1CHRM4SIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004207-A1 | THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL-AND PIPERIDINYL-ALKYL CARBAMATES | SANOFI-AVENTIS (FR) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004207-A1 | THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL-AND PIPERIDINYL-ALKYL CARBAMATES | CLCN2, CLIC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | HRH3 33/4885AOC3 167/4885HSD11B1 4153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.